1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016" provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Chronic Lymphocytic Leukemia (CLL) 30
Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax 30
Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting 30
Jun 06, 2016: TG Therapeutics Announces Long-Term Follow-up of TGR-1202 Demonstrates a Differentiated Safety Profile and High Response Rates in CLL and NHL in Data Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology 32
May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead 33
May 20, 2016: TG Therapeutics Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress 33
May 19, 2016: Ofatumumab Data to Be Presented at 21st Congress of EHA 33
May 18, 2016: Juno Therapeutics to Highlights New Efficacy, Safety, and Durability data for JCAR-014 at the 2016 American Society of Clinical Oncology Annual Meeting 34
May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 34
May 18, 2016: Juno Therapeutics to Highlight JCAR-015 at the 2016 American Society of Clinical Oncology Annual Meeting 35
May 18, 2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology 35
May 16, 2016: AbbVie announces The Lancet Oncology publication of Phase 2 data showing high overall response rates for Venetoclax in patients with relapsed/refractory chronic lymphocytic leukaemia with 17p deletion 36
May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients 37
Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 38
Apr 19, 2016: MacroGenics Presents Data from ROR1 x CD3 DART Preclinical Program at AACR Annual Meeting 2016 38
Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia 39
Clinical Trial Profile Snapshots 40
Appendix 1164
Abbreviations 1164
Definitions 1164
Research Methodology 1165
Secondary Research 1165
About GlobalData 1166
Contact Us 1166
Disclaimer 1166
Source 1167

List of Tables
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2016* 7
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 1165

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.